Compass Pathways builds a medical science liaison team to prepare commercial readiness for COMP360 psilocybin therapy ahead of possible regulatory approval

Compass Pathways is building a medical science liaison team as part of its commercial readiness strategy for COMP360, a proprietary psilocybin therapy being developed for treatment-resistant depression. The move signals preparation for a possible transition from late-stage clinical development toward launch planning, field medical education, and stakeholder engagement. Medical science liaisons typically support scientific exchange with clinicians, researchers, and health system decision makers rather than direct promotion. In this context, the team points to growing infrastructure around psychedelic medicine commercialization, where regulatory outcomes, therapist training, clinic capacity, and payer acceptance all shape adoption. COMP360 has become one of the most closely watched psilocybin programs in the sector, so expansion of field medical functions matters beyond one company. Commercial planning at this stage reflects how psychedelic therapies are moving from experimental settings toward mainstream healthcare pathways.